AstraZeneca, Cellworks partner to develop tuberculosis combination therapies
Under the collaboration, Cellworks will leverage its proprietary predictive platform to model drug MDR-TB and rationally identify synergistic combinations with highest possible efficacy and lowest possible toxic burden
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.